Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543526 | 1.00 | TACR1 (1.00) | TACR1 | |
| SCHEMBL3102542 | 1.00 | TACR1 (1.00) | TACR1 | |
| SCHEMBL2487997 | 1.00 | TACR1 (1.00) | TACR1 | |
| SCHEMBL8432621 | 1.00 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL8529468 | 0.99 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL29907288 | 0.99 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL8529474 | 0.99 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL8533298 | 0.99 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL8545811 | 0.99 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL17105739 | 0.98 | TACR1 (0.97) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218663-A1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2022-07-14 | — | — | US | disclosed |
| US-10729677-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-I | EUSTRALIS PHARMACEUTICAL LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2020-08-04 | — | — | US | disclosed |
| EP-3016642-B1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LTD TRADING AS PRESSURA NEURO (AU) | 2019-03-13 | — | — | EP | disclosed |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2019-02-12 | — | — | US | disclosed |
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-20160143881-A1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACETICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2016-05-26 | — | — | US | disclosed |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2016-02-04 | — | — | US | disclosed |
| US-9186404-B2 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2015-11-17 | — | — | US | disclosed |
| US-20100311803-A1 | METHOD FOR REDUCING INFLAMMATORY RESPONSES AND INFLAMMATION | ADELAIDE RESEARCH & INNOVATION PTY LTD | 2010-12-09 | — | — | US | disclosed |
| US-20100305183-A1 | METHOD AND COMPOSITION FOR REDUCING REPERFUSION INJURY | ADELAIDE RESEARCH & INNOVATION PTY LTD | 2010-12-02 | — | — | US | disclosed |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2005-05-19 | — | — | US | disclosed |
| US-6841551-B2 | Brain, spinal, and nerve injury treatment | HOFFMANN-LA ROCHE INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1261335-A4 | BRAIN, SPINAL AND NERVE INJURY TREATMENT | HOFFMANN LA ROCHE (CH) | 2004-09-22 | — | — | EP | disclosed |
| EP-1261335-A1 | BRAIN, SPINAL AND NERVE INJURY TREATMENT | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001052844-A1 | BRAIN, SPINAL AND NERVE INJURY TREATMENT | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| US-5843966-A | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0720609-B1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| US-5703240-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
| EP-0720609-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008549-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885 |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885 |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.